Shiladitya Sengupta - 13 Nov 2025 Form 4 Insider Report for Vyome Holdings, Inc (HIND)

Role: Director
Signature: /s/ Shiladitya Sengupta
Issuer symbol: HIND
Transactions as of: 13 Nov 2025
Transactions value $: $0
Form type: 4
Filing time: 17 Nov 2025, 19:36:39
Previous filing: 17 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Sengupta Shiladitya	Director	C/O VYOME HOLDINGS, INC., HARVARD SQUARE, ONE MIFFLIN PLC, ST. 400, CAMBRIDGE	/s/ Shiladitya Sengupta	17 Nov 2025	0001604700

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HIND	Stock Option (right to buy)	Award	$0	+624K		$0.00	624K	13 Nov 2025	Common Stock	624K	$0.66	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc.
F2	Pursuant to the Merger Agreement the reporting person was granted options to purchase 624,432 shares of the Issuer's common stock, all of which were fully vested as of the grant date. The options were granted under the Issuer's 2025 Equity Incentive Plan.

Content

Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc.

Pursuant to the Merger Agreement the reporting person was granted options to purchase 624,432 shares of the Issuer's common stock, all of which were fully vested as of the grant date. The options were granted under the Issuer's 2025 Equity Incentive Plan.